Chiang Mai University
cmu.ac.thTotal trials
116
Active
14
Phase 3
19
Total enrollment
22,726
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Furosemide | — | — | — | — | — | 1 | |
| Colistin Sodium Methanesulfonate | — | — | — | — | — | 1 | |
| Colistin Sodium Methanesulfonate plus Fosfomycin | — | — | — | — | — | 1 | |
| Inactivated hepatitis A vaccine | — | — | — | — | — | 1 | |
| MPFF | — | — | — | — | — | 1 | |
| Aescin in Horse Chestnut | — | — | — | — | 2 |
Next readouts
- 2025-03
- 2025-06-22
- 2025-07
- 2028-12-31
Top conditions
- Hypertension3
- Mild Cognitive Impairment3
- Acute Kidney Injury3
- HIV Infection3
- Hepatitis B3
- Peritoneal Dialysis3
- Hepatitis A3
- Vaccine-Preventable Diseases3
Frequently asked questions about Chiang Mai University
- How many clinical trials does Chiang Mai University have on ClinicalTrials.gov?
- Chiang Mai University is listed as the lead sponsor on 116 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chiang Mai University's trials are in Phase 3?
- 19 of Chiang Mai University's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does Chiang Mai University focus on?
- Chiang Mai University's most-studied conditions on ClinicalTrials.gov are Hypertension, Mild Cognitive Impairment, Acute Kidney Injury, HIV Infection, Hepatitis B.
- When are Chiang Mai University's next clinical trial readouts?
- Chiang Mai University has 4 upcoming primary-completion readouts tracked here; the soonest is “Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection”, expected around 2025-03.